# Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus

> **NCT00003326** · PHASE2 · UNKNOWN · sponsor: **Theradex** · enrollment: 100 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00003326
- **Lead sponsor:** Theradex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2008-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003326, "Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00003326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*